(Q54640393)

1 June 2018

title

Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. (English)

1 reference

1 June 2018

author

Tessa Buckle

2

1 reference

1 June 2018

Jos Beijnen

4

object named as

Jos H Beijnen

1 reference

1 June 2018

Jan H M Schellens

5

object named as

Jan H M Schellens

1 reference

1 June 2018

author name string

Nienke A de Vries

1

1 reference

1 June 2018

Jin Zhao

3

1 reference

1 June 2018

Olaf van Tellingen

6

1 reference

1 June 2018

publication date

21 October 2010

1 reference

1 June 2018

Investigational New Drugs

published in

1 reference

1 June 2018

volume

30

1 reference

1 June 2018

page(s)

443-449

1 reference

1 June 2018

issue

2

1 reference

1 June 2018

https://scigraph.springernature.com/pub.10.1007/s10637-010-9569-1

exact match

0 references

cites work

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

Targeting epidermal growth factor receptor--are we missing the mark?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

Update on epidermal growth factor receptor mutations in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

Structural alterations of the epidermal growth factor receptor gene in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

Phase II trial of gefitinib in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

The blood-brain barrier and cancer: transporters, treatment, and Trojan horses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec® ) across the mouse blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9569-1

Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme

21 January 2018

1 reference

12 December 2020

Molecular biology of the blood-brain barrier

1 reference

12 December 2020

Gefitinib reverses breast cancer resistance protein-mediated drug resistance

1 reference

12 December 2020

Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance

1 reference

12 December 2020

Blood-brain barrier drug targeting: the future of brain drug development

1 reference

12 December 2020

Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.

1 reference

12 December 2020

10.1007/S10637-010-9569-1

Identifiers

DOI

1 reference

1 June 2018

PubMed ID

20963470

1 reference

1 June 2018